Stay updated on Avutometinib + Defactinib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Avutometinib + Defactinib in Lung Cancer Clinical Trial page.

Latest updates to the Avutometinib + Defactinib in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page presents the details of a completed Phase 2 study of avutometinib alone or with defactinib for recurrent KRAS- or BRAF-mutant non-small cell lung cancer. It includes the study design, eligibility requirements, outcomes, investigators, and participating locations.SummaryDifference71%

- Check18 days agoChange DetectedThe site revision label in the footer changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden message instead of the study record.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1 while the page remains a 403 error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home button, indicating the study record is inaccessible; this replaces the previously visible study details and metadata.SummaryDifference18%

Stay in the know with updates to Avutometinib + Defactinib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avutometinib + Defactinib in Lung Cancer Clinical Trial page.